Archives
- 2018-07
- 2019-06
- 2019-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Since TgGC resisted several knockout attempts with CRISPR
2022-07-04
Since TgGC resisted several knockout attempts with CRISPR-Cas9, we utilized traditional epitope tagging and an auxin-inducible degron (AID) system (Brown et al., 2017, Brown et al., 2018, Long et al., 2017) to detect and regulate TgGC expression. TgGC localizes to the apical cap region of the plasm
-
GSTP c C T SNP was
2022-07-04
GSTP1 c.341C > T SNP was genotyped in 90 patients tumor and 180 normal healthy individuals. The profile of GSTP1 c.341C > T ARCA EGFP mRNA and genotypes is shown in Table 2. The profile of the genotypes was in agreement with Hardy-Weinberg equilibrium (χ2 = 2.11). Minor allele frequency (341T) amon
-
The diversity of biological properties
2022-07-04
The melanin inhibitor of biological properties and interactions of GSK-3 have been reviewed recently (, , , , ). The interactions of GSK-3 in the signaling pathways induced by nutraceuticals is covered in the review by ) in this special issue of . GSK-3 is a frequent target of many nutraceuticals s
-
br Introduction Nicotinic acid has been used
2022-07-04
Introduction Nicotinic TTNPB has been used clinically for more than 50 years [1] since it has anti-atherogenic effects, including the ability to reduce triglyceride (TG) and low-density lipoprotein cholesterol (LDL-C), and elevate high-density lipoprotein cholesterol (HDL-C) [2]. Nicotinic acid
-
br Clinical development of anti NASH
2022-07-04
Clinical development of anti-NASH drug therapies The current understanding of NASH pathogenesis has led to broad efforts to target several features of the disease, alone or in combination, even in the absence of liver-guided therapies. Therefore, drug development in NASH is a rapidly changing fie
-
src kinase inhibitor Based on the role of NMDA receptors in
2022-07-04
Based on the role of NMDA receptors in initiation and propagation of epileptic seizures and on potentiation of NMDA function by glycine, it has been hypothesized that glycine will have proconvulsant activity (Foster and Kemp, 1989). Indeed, there is some evidence that human epileptogenic foci, remov
-
In experiments using D to displace binding of specific
2022-07-04
In experiments using D22 to displace binding of specific high-affinity radioligands for DAT, NET, and SERT in mouse tropisetron synthesis tissue, we observed a ranking with D22 displacement efficiency in the order of DAT > SERT > NET (IC50 values being ~ 11 (DAT), 26 (SERT), and 101 (NET) µM; Fig. 1
-
One possible pathway summarizing the overall action involves
2022-07-04
One possible pathway summarizing the overall action involves NMDA receptor activation – Ca2+ influx – protein kinase A (PKA) activation – ERK phosphorylation and subsequent synaptic plasticity (Thomas and Huganir, 2004). A few studies have also shown modulation of synaptic glutamate transporters in
-
We also demonstrated that inhibition of NAAG hydrolysis to s
2022-07-04
We also demonstrated that inhibition of NAAG hydrolysis to suppress glutamate production through a GCPII inhibitor is a viable target for cancer therapy. GCPII is also known as N-acetyl-L-aspartyl-L-glutamate peptidase I (NAALADase I) or NAAG peptidase (Pinto et al., 1996), and its increased expres
-
In this study we present the synthesis
2022-07-04
In this study, we present the synthesis and structure–activity studies of a structurally distinct series possessing high potency and selectivity in HEK cell lines together with a potentially promising overall biopharmacological profile. Focusing on creating sufficient structural dissimilarity with g
-
br Methods br Results br Discussion The measurement of intra
2022-07-04
Methods Results Discussion The measurement of intraocular pressure was made with a commercially available rebound tonometer, the Tonovet®. In our studies, Tonovet® underestimated the intraocular pressure in both animal models, being this effect more pronounced in the rat. To study the effe
-
br Materials and methods br Results
2022-07-04
Materials and methods Results Discussion Employment of GIPR signaling, specifically the direction of this manipulation, as a strategy to improve body weight remains a contentious subject of intense scientific investigation [22], [32], [33]. Despite the physiological benefits of GIP on Litho
-
Nicastrin is heavily glycosylated contributing
2022-07-04
Nicastrin is heavily glycosylated, contributing 40–70KDa to the molecular weight of human γ-secretase. Among the 16 predicted N-linked glycosylation sites in the ECD, 11 have been unambiguously identified. The glycans appear to mostly stabilize the local structure, thus contributing to the folding a
-
We detected the FFAR protein with a
2022-07-02
We detected the FFAR2 protein with a molecular mass of about 50 kDa, which is comparable to the main band detected in pigs (Li et al., 2014) but different from the calculated size based on the sequence (Wang et al., 2009). The size difference can be explained, at least in part, by glycosylation site
-
To meet the requirement of ferroptosis based therapy
2022-07-02
To meet the requirement of ferroptosis-based therapy, a couple of small molecule drugs and nanomaterials were introduced to the design of ferroptosis inducers, separately. As we know, iron is a key regulator of ferroptosis. When small molecule drugs are employed to induce ferroptosis, the endogenous
14706 records 376/981 page Previous Next First page 上5页 376377378379380 下5页 Last page